fluoxetine has been researched along with Cerebral Ischemia in 25 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This trial compared the functional outcomes of subjects poststroke receiving fluoxetine versus placebo." | 9.41 | Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic. ( Alcott, SB; Demaerschalk, BM; Knox, MG; Marks, LA; O'Carroll, CB; Wingerchuk, DM, 2021) |
| "To determine if fluoxetine 20 mg by mouth daily, given within 14 days of acute ischemic stroke, and taken for 90 days, is well-tolerated and safe with adequate adherence to justify a future randomized, controlled trial of fluoxetine in the United Republic of Tanzania." | 9.34 | MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial. ( Buma, D; Chiwanga, F; Ismail, SS; Mateen, FJ; Okeng'o, K; Pothier, L; Vogel, AC, 2020) |
| "To evaluate the effect of fluoxetine on three-year recurrence rate of acute ischemic stroke." | 9.27 | Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. ( Cai, Z; Chang, X; Chen, S; Guo, Y; He, Y; Liang, Y; Tang, B; Zeng, S, 2018) |
| "We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke." | 9.22 | Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China. ( Cai, ZL; Guo, Y; He, YT; Jiang, X; Tang, BS; Zeng, SL, 2016) |
| "To evaluate the effect of using fluoxetine at different time intervals after ischemic stroke on neurological functional prognosis in China." | 9.22 | Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. ( Cai, Z; Guo, Y; He, Y; Jiang, X; Ma, K; Tang, B; Zeng, S; Zhang, Y, 2016) |
| "Our study aimed to evaluate the effect of fluoxetine on morning blood pressure surge (MBPS) in patients with ischemic stroke." | 8.02 | The effect of fluoxetine on morning blood pressure surge in patients with ischemic stroke: a prospective preliminary clinical study. ( Cai, Z; Deng, J; Guo, Y; He, Y; Zhang, H; Zhang, Y, 2021) |
| "Three large trials of fluoxetine for stroke recovery (FOCUS (fluoxetine or control under supervision), AFFINITY (the Assessment oF FluoxetINe In sTroke recovery) and EFFECTS (Efficacy oF Fluoxetine-a randomisEd Controlled Trial in Stroke)) have been collaboratively designed with the same basic protocol to facilitate an individual patient data analysis (IPDM)." | 7.96 | Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. ( Billot, L; Dennis, M; Forbes, J; Graham, C; Hackett, ML; Hankey, GJ; Lewis, S; Lundström, E; Mead, GE; Näsman, P, 2020) |
| "The serotonin selective reuptake inhibitor fluoxetine (Flx) has tried to treat patients suffered acute ischemic stroke because of its possible neuroprotective actions." | 7.78 | Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke. ( Sun, Y; Sun, ZQ; Yang, G; Zhou, CH; Zhu, BG; Zhu, RS, 2012) |
| "Fluoxetine treatment reduced the infarct size of rats after cerebral ischemia reperfusion injury." | 5.51 | Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus. ( Ge, MY; Li, Y; Peng, L; Wang, S; Xu, F; Yin, J; Zhang, G; Zhang, Q, 2019) |
| " This trial compared the functional outcomes of subjects poststroke receiving fluoxetine versus placebo." | 5.41 | Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic. ( Alcott, SB; Demaerschalk, BM; Knox, MG; Marks, LA; O'Carroll, CB; Wingerchuk, DM, 2021) |
| "To determine if fluoxetine 20 mg by mouth daily, given within 14 days of acute ischemic stroke, and taken for 90 days, is well-tolerated and safe with adequate adherence to justify a future randomized, controlled trial of fluoxetine in the United Republic of Tanzania." | 5.34 | MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial. ( Buma, D; Chiwanga, F; Ismail, SS; Mateen, FJ; Okeng'o, K; Pothier, L; Vogel, AC, 2020) |
| "To evaluate the effect of fluoxetine on three-year recurrence rate of acute ischemic stroke." | 5.27 | Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. ( Cai, Z; Chang, X; Chen, S; Guo, Y; He, Y; Liang, Y; Tang, B; Zeng, S, 2018) |
| "We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke." | 5.22 | Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China. ( Cai, ZL; Guo, Y; He, YT; Jiang, X; Tang, BS; Zeng, SL, 2016) |
| "To evaluate the effect of using fluoxetine at different time intervals after ischemic stroke on neurological functional prognosis in China." | 5.22 | Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. ( Cai, Z; Guo, Y; He, Y; Jiang, X; Ma, K; Tang, B; Zeng, S; Zhang, Y, 2016) |
| "Our study aimed to evaluate the effect of fluoxetine on morning blood pressure surge (MBPS) in patients with ischemic stroke." | 4.02 | The effect of fluoxetine on morning blood pressure surge in patients with ischemic stroke: a prospective preliminary clinical study. ( Cai, Z; Deng, J; Guo, Y; He, Y; Zhang, H; Zhang, Y, 2021) |
| "Three large trials of fluoxetine for stroke recovery (FOCUS (fluoxetine or control under supervision), AFFINITY (the Assessment oF FluoxetINe In sTroke recovery) and EFFECTS (Efficacy oF Fluoxetine-a randomisEd Controlled Trial in Stroke)) have been collaboratively designed with the same basic protocol to facilitate an individual patient data analysis (IPDM)." | 3.96 | Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. ( Billot, L; Dennis, M; Forbes, J; Graham, C; Hackett, ML; Hankey, GJ; Lewis, S; Lundström, E; Mead, GE; Näsman, P, 2020) |
| "Fluoxetine, a selective serotonin reuptake inhibitor, exerts neuroprotective effects in a variety of neurological diseases including stroke, but the underlying mechanism remains obscure." | 3.83 | Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53. ( Bian, Y; Ding, J; Hu, G; Lu, M; Shan, H; Shu, Z; Xiao, M; Zhang, L; Zhu, J, 2016) |
| "The serotonin selective reuptake inhibitor fluoxetine (Flx) has tried to treat patients suffered acute ischemic stroke because of its possible neuroprotective actions." | 3.78 | Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke. ( Sun, Y; Sun, ZQ; Yang, G; Zhou, CH; Zhu, BG; Zhu, RS, 2012) |
| " The aim of this study was to investigate the effects of the SSRIs citalopram and fluoxetine, on the corticocerebral blood flow (cCBF) in rabbits with unilateral carotid occlusion induced cerebral ischemia." | 3.74 | Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits. ( Csete, K; Papp, JG; Sas, K; Sztriha, L; Vécseil, L; Vezekényi, Z, 2007) |
| "Fluoxetine treatment reduced the infarct size of rats after cerebral ischemia reperfusion injury." | 1.51 | Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus. ( Ge, MY; Li, Y; Peng, L; Wang, S; Xu, F; Yin, J; Zhang, G; Zhang, Q, 2019) |
| "Fluoxetine treatment (10 mg/kg) after global ischemia significantly inhibited mRNA expression of MMP-2 and -9 and reduced MMP-9 activity." | 1.40 | Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood-brain barrier disruption. ( Choi, HY; Kang, SR; Lee, HE; Lee, JY; Ryu, JH; Yune, TY, 2014) |
| "Fluoxetine has been given to stroke patients to combat depression but its effects on recovery of function are not known." | 1.33 | Fluoxetine and recovery of motor function after focal ischemia in rats. ( Corbett, D; Windle, V, 2005) |
| "Serotonin syndrome is the result of the drug interaction that enhances serotonergic tone in the central nervous system." | 1.30 | Serotonin syndrome presenting with migrainelike stroke. ( Molaie, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vogel, AC | 1 |
| Okeng'o, K | 1 |
| Chiwanga, F | 1 |
| Ismail, SS | 1 |
| Buma, D | 1 |
| Pothier, L | 1 |
| Mateen, FJ | 1 |
| Mead, GE | 1 |
| Graham, C | 1 |
| Billot, L | 1 |
| Näsman, P | 1 |
| Lundström, E | 1 |
| Lewis, S | 1 |
| Hankey, GJ | 1 |
| Hackett, ML | 1 |
| Forbes, J | 1 |
| Dennis, M | 1 |
| He, Y | 3 |
| Deng, J | 1 |
| Zhang, Y | 2 |
| Cai, Z | 3 |
| Zhang, H | 1 |
| Guo, Y | 4 |
| Knox, MG | 1 |
| Demaerschalk, BM | 1 |
| Alcott, SB | 1 |
| Marks, LA | 1 |
| Wingerchuk, DM | 1 |
| O'Carroll, CB | 1 |
| Zeng, S | 2 |
| Chen, S | 1 |
| Tang, B | 2 |
| Liang, Y | 1 |
| Chang, X | 1 |
| Xu, F | 1 |
| Zhang, G | 1 |
| Yin, J | 1 |
| Zhang, Q | 1 |
| Ge, MY | 1 |
| Peng, L | 1 |
| Wang, S | 1 |
| Li, Y | 1 |
| Hua, Y | 1 |
| Li, C | 1 |
| Hu, J | 1 |
| Wang, YY | 1 |
| Liu, PL | 1 |
| Gao, BY | 1 |
| Chen, C | 1 |
| Xu, DS | 1 |
| Zhang, B | 1 |
| Bai, YL | 1 |
| Dhami, KS | 1 |
| Churchward, MA | 1 |
| Baker, GB | 1 |
| Todd, KG | 1 |
| Lee, JY | 1 |
| Lee, HE | 1 |
| Kang, SR | 1 |
| Choi, HY | 1 |
| Ryu, JH | 1 |
| Yune, TY | 1 |
| Corbett, AM | 1 |
| Sieber, S | 1 |
| Wyatt, N | 1 |
| Lizzi, J | 1 |
| Flannery, T | 1 |
| Sibbit, B | 1 |
| Sanghvi, S | 1 |
| Schambra, H | 1 |
| Im, B | 1 |
| O'Dell, MW | 1 |
| He, YT | 1 |
| Tang, BS | 1 |
| Cai, ZL | 1 |
| Zeng, SL | 1 |
| Jiang, X | 2 |
| Ma, K | 1 |
| Shan, H | 1 |
| Bian, Y | 1 |
| Shu, Z | 1 |
| Zhang, L | 1 |
| Zhu, J | 1 |
| Ding, J | 1 |
| Lu, M | 1 |
| Xiao, M | 1 |
| Hu, G | 1 |
| Sas, K | 2 |
| Gaillard, R | 1 |
| Mir, O | 1 |
| Gonzenbach, RR | 1 |
| Taegtmeyer, AB | 1 |
| Luft, A | 1 |
| Russmann, S | 1 |
| Taguchi, N | 1 |
| Nakayama, S | 1 |
| Tanaka, M | 1 |
| Zhu, BG | 1 |
| Sun, Y | 1 |
| Sun, ZQ | 1 |
| Yang, G | 1 |
| Zhou, CH | 1 |
| Zhu, RS | 1 |
| Ohira, K | 1 |
| Takeuchi, R | 1 |
| Shoji, H | 1 |
| Miyakawa, T | 1 |
| Zhao, CS | 1 |
| Puurunen, K | 1 |
| Schallert, T | 1 |
| Sivenius, J | 1 |
| Jolkkonen, J | 1 |
| Windle, V | 1 |
| Corbett, D | 1 |
| Csete, K | 1 |
| Vezekényi, Z | 1 |
| Sztriha, L | 1 |
| Vécseil, L | 1 |
| Papp, JG | 1 |
| Dam, M | 1 |
| Tonin, P | 1 |
| De Boni, A | 1 |
| Pizzolato, G | 1 |
| Casson, S | 1 |
| Ermani, M | 1 |
| Freo, U | 1 |
| Piron, L | 1 |
| Battistin, L | 1 |
| Molaie, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MAMBO: Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania[NCT03728153] | Phase 2 | 34 participants (Actual) | Interventional | 2019-11-26 | Completed | ||
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159] | Phase 2 | 52 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial[NCT00657163] | Phase 2 | 100 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Fugl Meyer motor scale is used to assess post-stroke motor recovery in stroke patients. It is scored on a scale from 0 to 100, with lower scores indicating greater disability. It evaluates both lower and upper extremities for motor performance: 66 points are allocated to the upper extremities, 34 to the lower extremities. The two extremities are summed to achieve the total score. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke
| Intervention | score on a scale (Mean) |
|---|---|
| 20mg Dose | 62.7 |
Validated instrument for measuring the degree of disability in stroke patients. The modified Rankin Scale is based on a physicians subjective evaluation. The scale ranges from 0, indicating perfect health, to 6, indicating that the patient is dead. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke
| Intervention | score on a scale (Median) |
|---|---|
| 20mg Dose | 2 |
10-item questionnaire used to evaluate the severity of a patient's depressive symptoms. Each item is scored on a scale from 0 to 6, the scores are summed, and the total score (0 to 60 points) is reported. The greater the score, the more severe the degree of depression. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke
| Intervention | units on a scale (Mean) |
|---|---|
| 20mg Dose | 5.6 |
Hepatic impairment was measured by elevation of hepatic enzyme (serum alanine aminotransferase; ALT) of >120 U/L (NCT03728153)
Timeframe: 90 days
| Intervention | U/L (Mean) |
|---|---|
| 20mg Dose | 28 |
Serum Sodium Concentration was measured in mmol/L. Hyponatremia was considered as <125 mmol/L. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke
| Intervention | mmol/L (Mean) |
|---|---|
| 20mg Dose | 138.7 |
The PHQ-9 is a validated 9-point questionnaire for measuring depression symptom severity. Each question is scored from 0-3. Answers are summed and the total score (0 to 27) is reported. The greater the score, the greater the severity of depression. (NCT03728153)
Timeframe: 90 days following acute ischemic stroke
| Intervention | units on a scale (Mean) |
|---|---|
| 20mg Dose | 4.6 |
1 review available for fluoxetine and Cerebral Ischemia
| Article | Year |
|---|---|
Should This Patient With Ischemic Stroke Receive Fluoxetine?
Topics: Aged; Brain Ischemia; Decision Making; Disability Evaluation; Fluoxetine; Humans; Male; Selective Se | 2015 |
7 trials available for fluoxetine and Cerebral Ischemia
| Article | Year |
|---|---|
MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial.
Topics: Brain Ischemia; Female; Fluoxetine; Humans; Male; Motor Activity; Recovery of Function; Selective Se | 2020 |
Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic.
Topics: Brain Ischemia; Fluoxetine; Humans; Recovery of Function; Selective Serotonin Reuptake Inhibitors; S | 2021 |
Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Female; Fluoxetine; Foll | 2018 |
Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China.
Topics: Brain Ischemia; China; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Prognosis; Selective Ser | 2016 |
Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; China; Double-Blind Meth | 2016 |
Fluoxetine has neuroprotective effects after cardiac arrest and cardiopulmonary resuscitation in mouse.
Topics: Animals; Brain; Brain Ischemia; Cardiopulmonary Resuscitation; Fluoxetine; Heart Arrest; Male; Mice; | 2012 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Activities of Daily Living; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Genera | 1996 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Activities of Daily Living; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Genera | 1996 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Activities of Daily Living; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Genera | 1996 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Activities of Daily Living; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Genera | 1996 |
17 other studies available for fluoxetine and Cerebral Ischemia
| Article | Year |
|---|---|
Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis.
Topics: Aged; Brain Ischemia; Data Interpretation, Statistical; Female; Fluoxetine; Humans; Male; Meta-Analy | 2020 |
The effect of fluoxetine on morning blood pressure surge in patients with ischemic stroke: a prospective preliminary clinical study.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brain Ischemia; Circadian Rhythm; Fluoxetine; | 2021 |
Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus.
Topics: Animals; Apoptosis; Brain Ischemia; Cognition; Endoplasmic Reticulum Stress; Fluoxetine; Hippocampus | 2019 |
Fluoxetine adjunct to therapeutic exercise promotes motor recovery in rats with cerebral ischemia: Roles of nucleus accumbens.
Topics: Animals; Brain Ischemia; Exercise Therapy; Fluoxetine; Infarction, Middle Cerebral Artery; Male; Mot | 2019 |
Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult.
Topics: Animals; Brain Ischemia; Cell Hypoxia; Cell Survival; Cells, Cultured; Cerebral Cortex; Citalopram; | 2013 |
Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood-brain barrier disruption.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain Ischemia; Capillary Permeability; Cell Death; Fluoxe | 2014 |
Increasing neurogenesis with fluoxetine, simvastatin and ascorbic Acid leads to functional recovery in ischemic stroke.
Topics: Animals; Ascorbic Acid; Brain; Brain Ischemia; Drug Therapy, Combination; Female; Fluoxetine; Male; | 2015 |
Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53.
Topics: Animals; Anisomycin; Apoptosis; bcl-2-Associated X Protein; Brain Ischemia; Cell Line, Tumor; Diseas | 2016 |
Potential role of glutamate neurotransmission in the pathogenesis of ischemic brain damage and of depression. Effects of L-kynurenine on the survival of the hippocampal neurons and on the corticocerebral blood flow in ischemic animal models.
Topics: Animals; Brain Ischemia; Cell Survival; Cerebrovascular Circulation; Chromatography, High Pressure L | 2010 |
Fluoxetine and motor recovery after ischaemic stroke.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2011 |
Fluoxetine and motor recovery after ischaemic stroke.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2011 |
Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke.
Topics: Animals; Brain Ischemia; Fluoxetine; Hypoxia, Brain; Male; Mice; Nitro Compounds; Propionates; Rando | 2012 |
Fluoxetine-induced cortical adult neurogenesis.
Topics: Age Factors; Animals; Brain Ischemia; Cerebral Cortex; Fluoxetine; Interneurons; Male; Mice; Mice, I | 2013 |
Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury.
Topics: Affect; Aggression; Aging; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; B | 2005 |
Fluoxetine and recovery of motor function after focal ischemia in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Infarction; Brain Ischemia; Fluoxetine; Male; | 2005 |
Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits.
Topics: Animals; Antidepressive Agents, Second-Generation; Blood Pressure; Brain Ischemia; Carotid Arteries; | 2007 |
Serotonin syndrome presenting with migrainelike stroke.
Topics: Adult; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Clomipramine; Confusi | 1997 |